There is an increasing demand for new cholesterol-lowering therapies in addition to existing treatments (e.g. targeting statins). The pharmacological inhibition of PCSK9-mediated LDLR degradation is becoming very attractive for treating cholesterol-related diseases. But which reliable in vitro assays are available to effectively study “PCSK9-LDLR” interactions ?
You are here: / Archives for PCSK9